Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis

Reuters

Nov 06, 2025

Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis $(PSC)$ will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 on November 10, 2025. The presentations will include results from the trial's open label extension, demonstrating nebokitug's favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug's macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570291-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581098029"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581098029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581098029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581098029","market":"nz","top_or_hot":-1,"title":"Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC\">$(PSC)$</a> will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 on November 10, 2025. The presentations will include results from the trial's open label extension, demonstrating nebokitug's favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug's macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570291-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC\">$(PSC)$</a> will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 on November 10, 2025. The presentations will include results from the trial's open label extension, demonstrating nebokitug's favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug's macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570291-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLrJcr:1","article_id":"2581098029","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581098029","pubTimestamp":1762434057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chemomab Therapeutics Ltd. announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis  will be presented at the American Association for the Study of Liver Disease  The Liver Meeting 2025 on November 10, 2025. The presentations will include results from the trial's open label extension, demonstrating nebokitug's favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug's macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","CMMB":"Chemomab Therapeutics Ltd.","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股"},"translate_title":"Chemomab报告Nebokitug治疗原发性硬化性胆管炎的积极2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CMMB":0.9},"content_text":"Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis\n    \n\nChemomab Therapeutics Ltd. announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis $(PSC)$ will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 on November 10, 2025. The presentations will include results from the trial's open label extension, demonstrating nebokitug's favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug's macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570291-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}